Skip to content

Study · Measured the body's own peptide · 1985

4 results

Origin and distribution of neuropeptide Y-, vasoactive intestinal polypeptide-and substance P-containing nerve fibers in the urinary bladder of the rat.

Mattiasson A, Ekblad E, Sundler F, Uvelius B

Cell and tissue research1 Jan 1985Cited by 89 (Europe PMC)

PMID2578316 (opens in a new tab)DOI10.1007/bf00214914 (opens in a new tab)PepBankPUB-02578316
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Natural levels measured4

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, VIP-containing fibres were richly present in the bladder, and VIP-containing nerve cell bodies were relatively rich in the pelvic ganglia.

    In plain wordsIn rats, the body's own VIP was found in nerve fibres in the bladder and nerve cells in nearby ganglia.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableVIP fibres and cell bodies in rat bladder and pelvic ganglia
    Study

    ratn: not reported in source

    urinary bladder and pelvic ganglia
    Outcome group
    Endogenous peptide levels · Kidney and urinary

    Source sentences

    Summary
    A rich occurrence of VIP fibers and a more sparse distribution of SP-containing fibers were also found in the bladder as well as a relatively rich representation of VIP-containing nerve cell bodies in the pelvic ganglia.
    1 context sentence
    Summary · context
    The origin and distribution in the urinary bladder of nerve fibers containing neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP) and substance P (SP) were investigated in rats.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  2. 02AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, preganglionic decentralization increased VIP immunofluorescence in nerve cell bodies of the pelvic ganglia and in nerve fibres of the bladder wall.

    In plain wordsIn rats, cutting the nerve supply before the ganglia raised the body's own VIP in nerve cells and bladder fibres.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    IncreaseVIP immunofluorescence after preganglionic decentralization
    Study

    ratn: not reported in source

    urinary bladder and pelvic ganglia
    Outcome group
    Endogenous peptide levels · Kidney and urinary

    Source sentences

    Summary
    After decentralization the intensity of VIP and NPY immunofluorescence increased in nerve cell bodies of the pelvic ganglia and in nerve fibers in the wall of the bladder.
    1 context sentence
    Summary · context
    The origin and distribution in the urinary bladder of nerve fibers containing neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP) and substance P (SP) were investigated in rats.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  3. 03AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, postganglionic denervation eliminated VIP and the other peptides examined in the bladder wall.

    In plain wordsIn rats, cutting the nerve supply after the ganglia removed the body's own VIP from the bladder wall.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP in bladder wall after postganglionic denervation
    Study

    ratn: not reported in source

    urinary bladder and pelvic ganglia
    Outcome group
    Endogenous peptide levels · Kidney and urinary

    Source sentences

    Summary
    Postganglionic denervation, on the other hand, eliminated all peptides examined in the bladder wall.
    1 context sentence
    Summary · context
    The origin and distribution in the urinary bladder of nerve fibers containing neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP) and substance P (SP) were investigated in rats.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

  4. 04AnimalEndogenous levelAnimal study (in vivo)Mechanism

    In rats, chemical sympathectomy with 6-OHDA did not significantly change the frequency and distribution of VIP fibres in the bladder muscle layer or pelvic ganglia.

    In plain wordsIn rats, a chemical that removes sympathetic nerves did not change the body's own VIP fibres in the bladder muscle or ganglia.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    No significant changeVIP fibres after chemical sympathectomy
    Study

    ratn: not reported in source

    urinary bladder and pelvic ganglia
    Outcome group
    Endogenous peptide levels · Kidney and urinary

    Source sentences

    Summary
    Chemical sympathectomy (6-OHDA) did not seem to change significantly the frequency and distribution of VIP-, SP- and NPY-fibers in the muscle layer of the bladder or in the pelvic ganglia, while the NPY-containing nerve fibers in the submucosal layer and around blood vessels of the bladder disappeared.
    1 context sentence
    Summary · context
    The origin and distribution in the urinary bladder of nerve fibers containing neuropeptide Y (NPY), vasoactive intestinal polypeptide (VIP) and substance P (SP) were investigated in rats.

    This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.